NASDAQ: GWPH - GW Pharmaceuticals plc

Yield per half year: 0%
Sector: Healthcare

Download the report: word Word , pdf PDF

1. Summary

Advantages

  • Positive review The stock's return over the last year (0%) is higher than the sector average (-92.54%).

Disadvantages

  • Negative review Price (218 $) is higher than fair price (194.76 $)
  • Negative review Dividends (0%) are below the sector average (1.871%).
  • Negative review The company's current efficiency (ROE=-9.62%) is lower than the sector average (ROE=11.82%)

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

GW Pharmaceuticals plc Healthcare Index
7 days 0% -100% -0.9%
90 days 0% -93.2% 7%
1 year 0% -92.5% 30.7%

Positive review GWPH vs Sector: GW Pharmaceuticals plc has outperformed the "Healthcare" sector by 92.54% over the past year.

Negative review GWPH vs Market: GW Pharmaceuticals plc has significantly underperformed the market by -30.69% over the past year.

Positive review Stable price: GWPH is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: GWPH with weekly volatility of 0% over the past year.

3. Summary of the report

3.1. General

P/E: 91.14
P/S: 12.3

3.2. Revenue

EPS -2.16
ROE -9.62%
ROA -7.81%
ROIC -9.05%
Ebitda margin -11.03%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Negative review company.analysis.fundamental.minus11_title: The current price (218 $) is higher than the fair price (194.76 $).

Negative review Price is higher than fair: The current price (218 $) is 10.7% higher than the fair price.

4.2. P/E

Negative review P/E vs Sector: The company's P/E (91.14) is higher than that of the sector as a whole (42.58).

Negative review P/E vs Market: The company's P/E (91.14) is higher than that of the market as a whole (54.92).

4.2.1 P/E Similar companies

4.3. P/BV

Negative review P/BV vs Sector: The company's P/BV (9.4) is higher than that of the sector as a whole (4.69).

Negative review P/BV vs Market: The company's P/BV (9.4) is higher than that of the market as a whole (2.35).

4.3.1 P/BV Similar companies

4.4. P/S

Negative review P/S vs Sector: The company's P/S indicator (12.3) is higher than that of the sector as a whole (4.77).

Negative review P/S vs Market: The company's P/S indicator (12.3) is higher than that of the market as a whole (p_s_market}).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

Positive review EV/Ebitda vs Sector: The company's EV/Ebitda (-163.78) is lower than that of the sector as a whole (16.28).

Positive review EV/Ebitda vs Market: The company's EV/Ebitda (-163.78) is lower than that of the market as a whole (22.79).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Ebitda

Positive review Yield Trend: Rising and has grown by 135.56% over the last 5 years.

Negative review Earnings Slowdown: The last year's return (0%) is below the 5-year average return (135.56%).

Negative review Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (1404.06%).

5.4. ROE

Negative review ROE vs Sector: The company's ROE (-9.62%) is lower than that of the sector as a whole (11.82%).

Negative review ROE vs Market: The company's ROE (-9.62%) is lower than that of the market as a whole (31.82%).

5.5. ROA

Negative review ROA vs Sector: The company's ROA (-7.81%) is lower than that of the sector as a whole (6.99%).

Negative review ROA vs Market: The company's ROA (-7.81%) is lower than that of the market as a whole (6.37%).

5.6. ROIC

Negative review ROIC vs Sector: The company's ROIC (-9.05%) is lower than that of the sector as a whole (13.31%).

Negative review ROIC vs Market: The company's ROIC (-9.05%) is lower than that of the market as a whole (10.68%).

6. Finance

6.1. Assets and debt

Positive review Debt level: (0%) is quite low in relation to assets.

Negative review Increasing debt: over 5 years, the debt has increased from 0% to 0%.

Negative review Excess of debt: The debt is not covered by net income, percentage -62.29%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Negative review Low yield: The dividend yield of the company 0% is below the average for the sector '1.871%.

7.2. Stability and increase in payments

Negative review Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Negative review Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Negative review Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Positive review Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet